Relay has raised more than $1 billion on the promise that its protein motion technology can help it discover and develop better drugs in less time. Its efforts remain in early stages and, so far, don’t prove its approach can be more productive.
Still, there’s considerable interest in Relay and companies like it that aim to marry traditional drug-hunting methods with “computational” techniques that can help predict how drug candidates affect the protein targets they’re designed to go after.
